Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 7 Mar 2020)

 

Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies
Antibiotic resistance (ABR) poses a major threat to health and economic wellbeing worldwide. Reducing ABR will require government interventions to incentivise antibiotic development, prudent antibiotic use, in…
Authors: Mark Jit, Dorothy Hui Lin Ng, Nantasit Luangasanatip, Frank Sandmann, Katherine E. Atkins, Julie V. Robotham and Koen B. Pouwels
Citation: BMC Medicine 2020 18:38
Content type: Correspondence
Published on: 6 March 2020

Knowledge about cervical cancer and HPV immunization dropout rate among Brazilian adolescent girls and their guardians

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 7 Mar 2020)

 

Knowledge about cervical cancer and HPV immunization dropout rate among Brazilian adolescent girls and their guardians
Infections with Human Papillomavirus (HPV) are the main cause of cervical cancer. Since 2014, the HPV vaccine was introduced in the Brazilian National Vaccination Calendar. The purpose of this study was to ass…
Authors: Ana Carolina da Silva Santos, Nayara Nascimento Toledo Silva, Cláudia Martins Carneiro, Wendel Coura-Vital and Angélica Alves Lima
Citation: BMC Public Health 2020 20:301
Content type: Research article
Published on: 6 March 2020

Are countries’ self-reported assessments of their capacity for infectious disease control reliable? Associations among countries’ self-reported international health regulation 2005 capacity assessments and infectious disease control outcomes

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 7 Mar 2020)

 

Are countries’ self-reported assessments of their capacity for infectious disease control reliable? Associations among countries’ self-reported international health regulation 2005 capacity assessments and infectious disease control outcomes
This study aimed to evaluate associations among countries’ self-reported International Health Regulation 2005 (IHR 2005) capacity assessments and infectious disease control outcomes.
Authors: Feng-Jen Tsai and Mathuros Tipayamongkholgul
Citation: BMC Public Health 2020 20:282
Content type: Research article
Published on: 4 March 2020

A disclosure form for work submitted to medical journals – a proposal from the International Committee of Medical Journal Editors

Bulletin of the World Health Organization
Volume 98, Number 3, March 2020, 149-228
https://www.who.int/bulletin/volumes/98/3/en/

 

A disclosure form for work submitted to medical journals – a proposal from the International Committee of Medical Journal Editors
— Darren B. Taichman, Joyce Backus, Christopher Baethge, Howard Bauchner, Annette Flanagin, Fernando Florenzano, Frank A. Frizelle, Fiona Godlee, Laragh Gollogly, Abraham Haileamlak, Sung-Tae Hong, Richard Horton, Astrid James, Christine Laine, Pamela W. Miller, Anja Pinborg, Eric J. Rubin & Peush Sahni
http://dx.doi.org/10.2471/BLT.20.252353

Measuring antibiotic availability and use in 20 low- and middle-income countries

Bulletin of the World Health Organization
Volume 98, Number 3, March 2020, 149-228
https://www.who.int/bulletin/volumes/98/3/en/

 

RESEARCH
Measuring antibiotic availability and use in 20 low- and middle-income countries
— Rebecca Knowles, Mike Sharland, Yingfen Hsia, Nicola Magrini, Lorenzo Moja, Amani Siyam & Elizabeth Tayler
http://dx.doi.org/10.2471/BLT.19.241349

Public-private knowledge transfer and access to medicines: a systematic review and qualitative study of perceptions and roles of scientists involved in HPV vaccine research

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 7 Mar 2020]

 

Public-private knowledge transfer and access to medicines: a systematic review and qualitative study of perceptions and roles of scientists involved in HPV vaccine research
Public research organizations and their interactions with industry partners play a crucial role for public health and access to medicines. The development and commercialization of the Human Papillomavirus (HPV) vaccines illustrate how licensing practices of public research organizations can contribute to high prices of the resulting product and affect accessibility to vulnerable populations. Efforts by the international community to improve access to medicines have recognised this issue and promote the public health-sensitive management of research conducted by public research organizations. This paper explores: how medical knowledge is exchanged between public and private actors; what role inventor scientists play in this process; and how they view the implementation of public health-sensitive knowledge exchange strategies.
Authors: Rosa Jahn, Olaf Müller, Stefan Nöst and Kayvan Bozorgmehr
Content type: Research
5 March 2020

Human Rights and Coronavirus: What’s at Stake for Truth, Trust, and Democracy?

Health and Human Rights
Volume 21, Issue 2, December 2019
https://www.hhrjournal.org/volume-21-issue-2-december-2019/

 

Viewpoints
Human Rights and Coronavirus: What’s at Stake for Truth, Trust, and Democracy?
Alicia Ely Yamin and Roojin Habibi
2 March 2020
Although World Health Organization (WHO) Director General Dr. Tedros Ghebreyesus has called for solidarity, not stigma, it is notable that to date WHO has not issued any substantive guidance on how countries can take public health measures that achieve health protection while respecting human rights.[2] Amid growing public fears, confusion, and misinformation, as well as government reactions that may fuel rather than mitigate intolerance, discrimination and exclusion, it is critical to set out some key human rights principles and the guidance they provide.[3]

The Crisis in Yemen

Humanitarian Exchange Magazine
Number 76, January 2020
https://odihpn.org/magazine/the-crisis-in-yemen/

 

The Crisis in Yemen
by HPN
This edition of Humanitarian Exchange focuses on the crisis in Yemen. Since the war there began in 2014, thousands of civilians have been killed or injured and air strikes and ground operations have destroyed hospitals, schools and critical infrastructure. An estimated 80% of Yemenis need humanitarian assistance.

In the lead article, Laurie Lee highlights the critical role Yemenis and Yemeni organisations are playing in addressing the humanitarian challenges in the country, and how NGOs can better support them. Genevieve Gauthier and Marcus Skinner reinforce this point with reference to two local organisations, the Yemen Women’s Union and Al Hikma. Warda Saleh, the founder of another Yemeni grassroots organisation, discusses the increased risk of gender-based violence facing women and girls, while Ibrahim Jalal and Sherine El Taraboulsi-McCarthy focus on internal displacement and the opportunities for a more effective humanitarian response. Reflecting on child protection programming in Yemen, Mohammed Alshamaa  and Amanda Brydon conclude that multisectoral approaches with local authorities result in better and more sustainable outcomes. Padraic McCluskey and Jana Brandt consider the ethical dilemmas Médecins Sans Frontières (MSF) faced in trying to balance quality and coverage in a mother and child hospital in Taiz. Lindsay Spainhour Baker and colleagues reflect on the challenges involved in gathering and analysing information on the humanitarian situation while Lamis Al-Iryani, Sikandra Kurdi and Sarah Palmer-Felgate discuss the findings from an evaluation of the Yemen Social Fund for Development (SFD) Cash for Nutrition programme. An article by Kristine Beckerle and Osamah Al-Fakih details Yemeni and international organisations’ efforts to document and mitigate harm to civilians caught up in the conflict. The edition ends with a piece by Fanny Pettibon, Anica Heinlein and Dhabie Brown outlining CARE’s advocacy on the arms trade.

Finally, readers will note that this edition is shorter than usual, largely because it was very difficult to persuade potential authors to write on the Yemen crisis. Many of the individuals and organisations we contacted were either too busy responding or were concerned that writing frankly about their work could negatively affect their operations. HPN has covered many similarly sensitive contexts in Humanitarian Exchange over the last 26 years, but this is the first time we have experienced such reluctance to engage. A worrying sign.

Vaccinating pregnant women against influenza needs to be a priority for all countries: An expert commentary

International Journal of Infectious Diseases
March 2020 Volume 92, p1-272
https://www.ijidonline.com/issue/S1201-9712(20)X0002-6

 

Review
Vaccinating pregnant women against influenza needs to be a priority for all countries: An expert commentary
Philippe Buchy, Selim Badur, George Kassianos, Scott Preiss, John S. Tam
p1–12
Published online: December 18, 2019

Associations between geographic region and immune response variations to pneumococcal conjugate vaccines in clinical trials: A systematic review and meta-analysis

International Journal of Infectious Diseases
March 2020 Volume 92, p1-272
https://www.ijidonline.com/issue/S1201-9712(20)X0002-6

 

Original Reports
Associations between geographic region and immune response variations to pneumococcal conjugate vaccines in clinical trials: A systematic review and meta-analysis
Young June Choe, Daniel B. Blatt, Hoan Jong Lee, Eun Hwa Choi
p261–268
Published in issue: March 2020

Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies

JAMA
March 3, 2020, Vol 323, No. 9, Pages 809-902
http://jama.jamanetwork.com/issue.aspx

 

Drug Pricing
Original Investigation
Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies
Fred D. Ledley, MD; Sarah Shonka McCoy, PhD; Gregory Vaughan, PhD; et al.
has active quiz
JAMA. 2020;323(9):834-843. doi:10.1001/jama.2020.0442
Key Points
Question
How do the profits of large pharmaceutical companies compare with those of other companies from the S&P 500 Index?
Findings
In this cross-sectional study that compared the profits of 35 large pharmaceutical companies with those of 357 large, nonpharmaceutical companies from 2000 to 2018, the median net income (earnings) expressed as a fraction of revenue was significantly greater for pharmaceutical companies compared with nonpharmaceutical companies (13.8% vs 7.7%).
Meaning
Large pharmaceutical companies were more profitable than other large companies, although the difference was smaller when controlling for differences in company size, research and development expense, and time trends.

JAMA

JAMA
March 3, 2020, Vol 323, No. 9, Pages 809-902
http://jama.jamanetwork.com/issue.aspx

 

Abstract
Importance
Understanding the profitability of pharmaceutical companies is essential to formulating evidence-based policies to reduce drug costs while maintaining the industry’s ability to innovate and provide essential medicines.
Objective
To compare the profitability of large pharmaceutical companies with other large companies.
Design, Setting, and Participants
This cross-sectional study compared the annual profits of 35 large pharmaceutical companies with 357 companies in the S&P 500 Index from 2000 to 2018 using information from annual financial reports. A statistically significant differential profit margin favoring pharmaceutical companies was evidence of greater profitability.
Exposures  Large pharmaceutical vs nonpharmaceutical companies.
Main Outcomes and Measures
The main outcomes were revenue and 3 measures of annual profit: gross profit (revenue minus the cost of goods sold); earnings before interest, taxes, depreciation, and amortization (EBITDA; pretax profit from core business activities); and net income, also referred to as earnings (difference between all revenues and expenses). Profit measures are described as cumulative for all companies from 2000 to 2018 or annual profit as a fraction of revenue (margin).
Results
From 2000 to 2018, 35 large pharmaceutical companies reported cumulative revenue of $11.5 trillion, gross profit of $8.6 trillion, EBITDA of $3.7 trillion, and net income of $1.9 trillion, while 357 S&P 500 companies reported cumulative revenue of $130.5 trillion, gross profit of $42.1 trillion, EBITDA of $22.8 trillion, and net income of $9.4 trillion. In bivariable regression models, the median annual profit margins of pharmaceutical companies were significantly greater than those of S&P 500 companies (gross profit margin: 76.5% vs 37.4%; difference, 39.1% [95% CI, 32.5%-45.7%]; P < .001; EBITDA margin: 29.4% vs 19%; difference, 10.4% [95% CI, 7.1%-13.7%]; P < .001; net income margin: 13.8% vs 7.7%; difference, 6.1% [95% CI, 2.5%-9.7%]; P < .001). The differences were smaller in regression models controlling for company size and year and when considering only companies reporting research and development expense (gross profit margin: difference, 30.5% [95% CI, 20.9%-40.1%]; P < .001; EBITDA margin: difference, 9.2% [95% CI, 5.2%-13.2%]; P < .001; net income margin: difference, 3.6% [95% CI, 0.011%-7.2%]; P = .05).
Conclusions and Relevance
From 2000 to 2018, the profitability of large pharmaceutical companies was significantly greater than other large, public companies, but the difference was less pronounced when considering company size, year, or research and development expense. Data on the profitability of large pharmaceutical companies may be relevant to formulating evidence-based policies to make medicines more affordable.

Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018

JAMA
March 3, 2020, Vol 323, No. 9, Pages 809-902
http://jama.jamanetwork.com/issue.aspx

 

Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Olivier J. Wouters, PhD; Martin McKee, MD, DSc; Jeroen Luyten, PhD
JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166
This study uses publicly available data to analyze research and development spending to win FDA approval and bring new drugs to market between 2009 and 2018.

Sponsorship and Funding for Gene Therapy Trials in the United States

JAMA
March 3, 2020, Vol 323, No. 9, Pages 809-902
http://jama.jamanetwork.com/issue.aspx

 

Research Letter
Sponsorship and Funding for Gene Therapy Trials in the United States
Zachary Kassir, BA; Ameet Sarpatwari, PhD, JD; Brian Kocak, BS; et al.
March 3, 2020
JAMA. 2020;323(9):890-891. doi:10.1001/jama.2019.22214
Since 2017, the US Food and Drug Administration (FDA) has approved 4 gene therapies: tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) for cancer, voretigene neparvovec-rzyl (Luxturna) for a genetic form of blindness, and onasemnogene abeparvovec-xioi (Zolgensma) for spinal muscular atrophy. Although clinically transformative, they carry list prices of $475 000, $373 000, $425 000, and $2.1 million, respectively, for 1-time infusions. High development costs and the need to incentivize innovation are common justifications for such prices. However, public funding played an important role in each product’s invention and clinical testing.15

Health Departments’ Experience With Mumps Outbreak Response and Use of a Third Dose of Measles, Mumps, and Rubella Vaccine

Journal of Public Health Management & Practice
March/April 2020 – Volume 26 – Issue 2
https://journals.lww.com/jphmp/pages/currenttoc.aspx

 

Practice Full Report
Health Departments’ Experience With Mumps Outbreak Response and Use of a Third Dose of Measles, Mumps, and Rubella Vaccine
Marlow, Mariel A.; Moore, Kelly; DeBolt, Chas; More
Journal of Public Health Management and Practice. 26(2):101-108, March/April 2020.

Beyond Research Ethics: Novel Approaches of 3 Major Public Health Institutions to Provide Ethics Input on Public Health Practice Activities

Journal of Public Health Management & Practice
March/April 2020 – Volume 26 – Issue 2
https://journals.lww.com/jphmp/pages/currenttoc.aspx

 

Beyond Research Ethics: Novel Approaches of 3 Major Public Health Institutions to Provide Ethics Input on Public Health Practice Activities
Klingler, Corinna; Barrett, Drue H.; Ondrusek, Nancy; More
Journal of Public Health Management and Practice. 26(2):E12-E22, March/April 2020.

Vaccination Capability Inventory of Community, Migrant, and Homeless Health Centers: A Survey Report

Journal of Public Health Management & Practice
March/April 2020 – Volume 26 – Issue 2
https://journals.lww.com/jphmp/pages/currenttoc.aspx

 

Research Full Report
Vaccination Capability Inventory of Community, Migrant, and Homeless Health Centers: A Survey Report
Federally funded Community, Migrant, and Homeless Health Centers provide health services to the most vulnerable communities in the United States. However, little is known about their capabilities and processes for providing vaccinations to adults….Health centers provide most adult vaccines to their patients despite financial and technological barriers to optimal provisioning. Further studies at point of care could help identify mechanisms for system improvements.
Lewis, Joy H.; Whelihan, Kate; Roy, Debosree; More
Journal of Public Health Management and Practice. 26(2):139-147, March/April 2020.

Toward Optimal Communication About HPV Vaccination for Preteens and Their Parents: Evaluation of an Online Training for Pediatric and Family Medicine Health Care Providers

Journal of Public Health Management & Practice
March/April 2020 – Volume 26 – Issue 2
https://journals.lww.com/jphmp/pages/currenttoc.aspx

 

Toward Optimal Communication About HPV Vaccination for Preteens and Their Parents: Evaluation of an Online Training for Pediatric and Family Medicine Health Care Providers
Cates, Joan R.; Diehl, Sandra J.; Fuemmeler, Bernard F.; More
Journal of Public Health Management and Practice. 26(2):159-167, March/April 2020.

Local Health Department Interest in Implementation of a Jail-Based Human Papillomavirus Vaccination Program in Kansas, Iowa, Missouri, and Nebraska

Journal of Public Health Management & Practice
March/April 2020 – Volume 26 – Issue 2
https://journals.lww.com/jphmp/pages/currenttoc.aspx

 

Local Health Department Interest in Implementation of a Jail-Based Human Papillomavirus Vaccination Program in Kansas, Iowa, Missouri, and Nebraska
Local health departments (LHDs) play a vital role in community vaccination programs for human papillomavirus (HPV) infection, but little research has been done to assess LHD interest in cross-sectoral partnerships to vaccinate high-risk groups, specifically incarcerated persons… Nearly half of LHDs in the region expressed interest in partnering with local entities to meet HPV vaccination needs of high-risk groups. Research on cross-sectoral partnerships and what these collaborations look like in practice is needed for public health impact.
Ramaswamy, Megha; Allison, Molly; Musser, Brynne; More
Journal of Public Health Management and Practice. 26(2):168-175, March/April 2020.

Population implications of the deployment of novel universal vaccines against epidemic and pandemic influenza

Journal of the Royal Society – Interface
01 March 2020 Volume 17 Issue 164
https://royalsocietypublishing.org/toc/rsif/current

 

Report
Population implications of the deployment of novel universal vaccines against epidemic and pandemic influenza
N. Arinaminpathy, S. Riley, W. S. Barclay, C. Saad-Roy and B. Grenfell
Published: 04 March 2020 Article ID:20190879
There is increasing interest in the development of new, ‘universal’ influenza vaccines (UIVs) that––unlike current vaccines––are effective against a broad range of seasonal influenza strains, as well as against novel pandemic viruses.

COVID-19: too little, too late?

The Lancet
Mar 07, 2020 Volume 395 Number 10226 p755-838, e42-e45
https://www.thelancet.com/journals/lancet/issue/current

 

Editorial
COVID-19: too little, too late?
The Lancet
Although WHO has yet to call the outbreak of SARS-CoV-2 infection a pandemic, it has confirmed that the virus is likely to spread to most, if not all, countries. Regardless of terminology, this latest coronavirus epidemic is now seeing larger increases in cases outside China. As of March 3, more than 90 000 confirmed cases of COVID-19 have been reported in 73 countries. The outbreak in northern Italy, which has seen 11 towns officially locked down and residents threatened with imprisonment if they try to leave, shocked European political leaders. Their shock turned to horror as they saw Italy become the epicentre for further spread across the continent. As the window for global containment closes, health ministers are scrambling to implement appropriate measures to delay spread of the virus. But their actions have been slow and insufficient. There is now a real danger that countries have done too little, too late to contain the epidemic.

By striking contrast, the WHO-China joint mission report calls China’s vigorous public health measures toward this new coronavirus probably the most “ambitious, agile and aggressive disease containment effort in history”. China seems to have avoided a substantial number of cases and fatalities, although there have been severe effects on the nation’s economy. In its report on the joint mission, WHO recommends that countries activate the highest level of national response management protocols to ensure the all-of-government and all-of-society approaches needed to contain viral spread. China’s success rests largely with a strong administrative system that it can mobilise in times of threat, combined with the ready agreement of the Chinese people to obey stringent public health procedures. Although other nations lack China’s command-and-control political economy, there are important lessons that presidents and prime ministers can learn from China’s experience. The signs are that those lessons have not been learned.

SARS-CoV-2 presents different challenges to high-income and low-income or middle-income countries (LMICs). A major fear over global spread is how weak health systems will cope. Some countries, such as Nigeria, have so far successfully dealt with individual cases. But large outbreaks could easily overwhelm LMIC health services. The difficult truth is that countries in most of sub-Saharan Africa, for example, are not prepared for an epidemic of coronavirus. And nor are many nations across Latin America and the Middle East. Public health measures, such as surveillance, exhaustive contact tracing, social distancing, travel restrictions, educating the public on hand hygiene, ensuring flu vaccinations for the frail and immunocompromised, and postponing non-essential operations and services will all play their part in delaying the spread of infection and dispersing pressure on hospitals. Individual governments will need to decide where they draw the line on implementing these measures. They will have to weigh the ethical, social, and economic risks versus proven health benefits.

The evidence surely indicates that political leaders should be moving faster and more aggressively. As Xiaobo Yang and colleagues have shown, the mortality of critically ill patients with SARS-CoV-2 pneumonia is substantial. As they wrote recently in The Lancet Respiratory Medicine, “The severity of SARS-CoV-2 pneumonia poses great strain on critical care resources in hospitals, especially if they are not adequately staffed or resourced.” This coronavirus is not benign. It kills. The political response to the epidemic should therefore reflect the national security threat that SARS-CoV-2 represents.

National governments have all released guidance for health-care professionals, but published advice alone is insufficient. Guidance on how to manage patients with COVID-19 must be delivered urgently to health-care workers in the form of workshops, online teaching, smart phone engagement, and peer-to-peer education. Equipment such as personal protective equipment, ventilators, oxygen, and testing kits must be made available and supply chains strengthened. The European Centre for Disease Prevention and Control recommends that hospitals set up a core team including hospital management, an infection control team member, an infectious disease expert, and specialists representing the intensive care unit and accident and emergency departments.

So far, evidence suggests that the colossal public health efforts of the Chinese Government have saved thousands of lives. High-income countries, now facing their own outbreaks, must take reasoned risks and act more decisively. They must abandon their fears of the negative short-term public and economic consequences that may follow from restricting public freedoms as part of more assertive infection control measures.

Children on the move—a call for active screening in migrants

The Lancet Child & Adolescent Health
Feb 2020 Volume 4 Number 2 p91-166, e5
https://www.thelancet.com/journals/lanchi/issue/current

 

Comment
Children on the move—a call for active screening in migrants
Ulrich von Both
Paediatricians, general practitioners, and family doctors are increasingly confronted with medical symptoms previously not on their radar, because of a rise in migration. In the past 5 years, an estimated 1 million displaced children and adolescents have entered the EU and European Economic Area (EEA), many of them unaccompanied. This vulnerable group faces great challenges and health risks. Societies should welcome migrant families, and medical professionals should help integrate migrant children into health-care systems to ensure high quality care is delivered sustainably. Besides obvious benefits for the individual, it is in the interest of societies to prevent increased incidence of infectious diseases that are currently well controlled, such as tuberculosis. Three infectious diseases—tuberculosis, schistosomiasis, and strongyloidiasis—are particularly relevant and should be seen as priorities for screening and treatment in migrant children.

Child and adolescent health in the digital age

Lancet Digital Health
Feb 2020 Volume 2 Number 2 e49-e101
https://www.thelancet.com/journals/landig/issue/current

 

Editorial
Child and adolescent health in the digital age
The Lancet Digital Health
On 18 February, 2020, The Lancet published the report of the WHO-UNICEF-Lancet Commission, calling for a refocus of the Sustainable Development Goals (SDGs) around child and adolescent health. All sectors are responsible for children’s wellbeing, with digital platforms and artificial intelligence (AI) playing an increasing role in child and adolescent health.

The Commission argues that open dialogue across generations is essential to understand the needs of children and adolescents, especially in low- and middle-income countries (LMICs) where 90% of the global youth population currently live. Digital technologies, such as social media and AI-based chatbots, have much to offer in this regard. The Commission highlights that adolescents are enthusiastic users of technology, with those aged 11–16 years posting on social media on average 26 times a day. With a predicted 40 times increase of their global volume of data, adolescents who might seldom access traditional health services, could more easily be reached through digital health platforms. For example, the Commission describes U-Report, a mobile-based online poll for real-time data collection, which collates opinions from approximately 1 million youths from over 50 LMICs to better communicate with government officials to strengthen public health campaigns, such as immunisation awareness.

Despite the development of promising digital interventions, the Commission calls for further research to understand ways to positively engage with adolescents about health issues using digital technology. A paper in The Lancet Digital Health, by Maree Teesson and colleagues, reported a cluster-randomised controlled trial in 71 schools in Australia, which showed efficacy of an online digital intervention for prevention of substance use, depression, and anxiety in adolescents. This digital intervention allows scaling up of prevention programmes, which could reduce costs and increase accessibility to lower resource settings. However, further trials are necessary to determine whether this intervention is cost effective and if the benefits are sustained beyond the trial phase.

The Commission cites several digital interventions that have shown potential in engaging adolescents about health issues; however, the report does not mention augmented reality, a burgeoning area of research in child and adolescent health. In The Lancet Digital Health, Kollins and colleagues describe a randomised controlled trial to test the efficacy of a video game-like interface designed to support children with attention deficit hyperactivity disorder. The results of the trial show that this digital intervention can increase attentional functioning of children with the disorder, but future trials are necessary to examine the durability and time course of the intervention.

The prevalent use of digital platforms, such as social media, has encouraged speculation that their regular use might negatively effect child and adolescent health, a concern echoed within the Commission. However, current evidence supporting this idea is controversial due to the nature of the large-scale social datasets used in many studies which could be prone to potential false positives and conflicting results. A study attempted to address these challenges using three large-scale social datasets and found no significant correlational evidence for detrimental effects of digital technology on adolescent health.

The Commission ends with the quote “what gets measured, gets done”, which highlights a well known barrier to achieving the SDGs: inability to collect the necessary quality and volume of data to monitor progress. Open data is needed to overcome the barriers to collect and share data for SDG progress, and the Commission authors rightly demand better use of data from publicly available sources. However, there are concerns regarding the few safeguards to protect children’s data, especially against data manipulation through black box and biased algorithms. The Commission also highlights the shortcomings of current data privacy regulations, emphasising that public sector bodies and commercial organisations have failed to ensure privacy, transparency, security, and redress when handling children’s data. The assurance of privacy and security of data is key to the success of digital innovation and transformation of health care.

Digital platforms and AI are necessary tools to enable children and adolescents to be agents of change, encouraging open dialogue between children, international agencies, and governments to achieve the SDGs for a better future.

Challenges of coronavirus disease 2019

Lancet Infectious Diseases
Mar 2020 Volume 20 Number 3 p261-382, e27-e49
http://www.thelancet.com/journals/laninf/issue/current

 

Editorial
Challenges of coronavirus disease 2019
The Lancet Infectious Diseases
Yet again, the world is experiencing a global viral epidemic of zoonotic origin. As of Feb 12, 45 204 confirmed cases of coronavirus disease 2019 (COVID-19) and 1116 deaths had been reported in 25 countries. The majority of cases and, at the time of writing, all but one death have been in China, despite efforts in the country to halt transmission through shutting down transport, quarantining entire cities, and enforcing the use of face masks. International flights have been cancelled and affected cruise ships quarantined. At this stage, it is unclear whether the severe acute respiratory syndrome coronavirus (SARS-CoV)-2 outbreak will run its course, as SARS-CoV did in 2003, or will become an endemic cause of viral pneumonia.

In our January issue we announced the formation of The Lancet Infectious Diseases Commission on Preparedness for Emerging Epidemic Threats. The Commission will revisit global preparedness planning and assumptions underlying agreements such as the International Health Regulations. It aims to account for new challenges in preparing for and responding to infectious disease outbreaks. These challenges, which are political and institutional, social, environmental, technological, and pathogen-related, are being brought to the foreground by the SARS-CoV-2 outbreak.

Challenges of coronavirus disease 2019

Lancet Infectious Diseases
Mar 2020 Volume 20 Number 3 p261-382, e27-e49
http://www.thelancet.com/journals/laninf/issue/current

 

Challenges of coronavirus disease 2019
One issue is how prepared the world’s health systems are to respond to an outbreak of this scale. It’s clear the large number of cases of COVID-19 is testing the health system in China. Yet, China was able to build a hospital for affected patients in a matter of days. No other country could mobilise resources and manpower at such speed. While health systems in high-income countries would be stretched by the outbreak, the most devastating effects would be in countries with weak health systems, ongoing conflicts, or existing infectious disease epidemics.
In these countries, it is imperative to rapidly detect and contain the virus at points of entry to prevent community transmission and health systems from being overwhelmed. Health authorities in Africa are on high alert for the virus, given the continent’s extensive trade and transport links with Asia. The capacity in Africa to screen, isolate, and treat patients and perform contact tracing is being built under the leadership of the Africa Centres for Disease Control and Prevention and WHO.

As in all outbreaks, there is an urgent need to develop effective diagnostics, therapeutics, and vaccines. Several experimental diagnostic platforms are already in use in China and elsewhere. The whole-genome sequence of SARS-CoV-2 had been obtained and shared widely by mid-January, a feat not possible at such speed in previous infectious disease outbreaks. This sequence will allow fine-tuning of existing technologies and development of better diagnostics and targeted therapeutics. Several potential treatments have been proposed, including a Janus kinase inibitor known as baricitinib. However, no antiviral treatment has been approved for coronaviruses, and despite two outbreaks of novel coronaviruses in the past two decades, vaccine development is still in its infancy. WHO has announced that a vaccine for SARS-CoV-2 should be available in 18 months, but achieving this will require funding and public interest to be maintained even if the threat level falls.

Social media and sensationalist reporting are challenging outbreak response efforts. Misinformation and conspiracy theories spread on social media have generated panic and mistrust among the general public, diverted attention away from the outbreak response, and impeded the activities of health-care workers. WHO Director-General Tedros Adhanom Ghebreyesus said WHO is tackling the spread of false information with a “four-pronged approach”, including using its WHO Information Network for Epidemics platform to track misinformation in multiple languages and collaborating with social and digital companies such as Facebook, Weibo, and Twitter to filter out false information.

How prepared the world was for the SARS-CoV-2 outbreak will surely be discussed in its aftermath. The initial response in China to contain the virus was applauded by WHO and considered much improved compared with its response to the 2003 SARS-CoV epidemic. Internationally, we have seen rapid generation and sharing of knowledge to the benefit of the outbreak response, but also counterproductive actions by some countries, including limiting trade and shutting of borders, to its detriment. With the increasing frequency of zoonotic spillovers leading to human infections and transmission, it’s apparent that pandemic preparedness has become a priority for the global health agenda.

The status of tuberculosis vaccine development

Lancet Infectious Diseases
Mar 2020 Volume 20 Number 3 p261-382, e27-e49
http://www.thelancet.com/journals/laninf/issue/current

 

Review
The status of tuberculosis vaccine development
Lewis K Schrager, Johan Vekemens, Nick Drager, David M Lewinsohn, Ole F Olesen
Summary
Tuberculosis represents the leading global cause of death from an infectious agent. Controlling the tuberculosis epidemic thus represents an urgent global public health priority. Epidemiological modelling suggests that, although drug treatments for tuberculosis continue to improve, WHO timelines to control the spread of the disease require a new vaccine capable of preventing tuberculosis, particularly in adolescents and adults. The spread of strains resistant to multiple drugs adds additional urgency to the vaccine development effort yet attempts to develop new vaccines with wider applicability and better, longer-lasting efficacy than BCG—the only tuberculosis vaccine licensed for use globally—have proven challenging. Results from clinical efficacy trials, particularly a completed, phase 2b trial for preventing tuberculosis disease in people infected with Mycobacterium tuberculosis using the adjuvanted protein subunit vaccine M72/AS01E give hope. We review the current status of tuberculosis vaccine candidates and outline the diversified vaccine development that are underway.

Whole tumor genomes across cancers

Nature Genetics
Volume 52 Issue 3, March 2020
https://www.nature.com/ng/volumes/52/issues/3

 

Editorial | 05 March 2020
Whole tumor genomes across cancers
The Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium project, led by the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), coordinated the sequencing and analysis of 2,583 tumor whole genomes across 38 cancer types. This impressively large project, comprising many working groups focusing on various molecular or genetic features of cancer, has generated valuable data for the cancer research community that will continue to be mined for many years to come.

The landscape of viral associations in human cancers

Nature Genetics
Volume 52 Issue 3, March 2020
https://www.nature.com/ng/volumes/52/issues/3

 

Article | 05 February 2020 | Open Access
The landscape of viral associations in human cancers
Viral pathogen load in cancer genomes is estimated through analysis of sequencing data from 2,656 tumors across 35 cancer types using multiple pathogen-detection pipelines, identifying viruses in 382 genomic and 68 transcriptome datasets.
Marc Zapatka, Ivan Borozan[…] & Marc Zapatka

Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing

Nature Genetics
Volume 52 Issue 3, March 2020
https://www.nature.com/ng/volumes/52/issues/3

 

Analysis | 05 February 2020 | Open Access
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
Analysis of whole-genome sequencing data across 2,658 tumors spanning 38 cancer types shows that chromothripsis is pervasive, with a frequency of more than 50% in several cancer types, contributing to oncogene amplification, gene inactivation and cancer genome evolution.
Isidro Cortés-Ciriano, Jake June-Koo Lee[…] & Peter J. Park
Special: Pan-Cancer Analysis of Whole Genomes

Communication, collaboration and cooperation can stop the 2019 coronavirus

Nature Medicine
Volume 26 Issue 2, February 2020
https://www.nature.com/nm/volumes/26/issues/2

 

Editorial | 03 February 2020
Communication, collaboration and cooperation can stop the 2019 coronavirus
As the outbreak of a deadly new coronavirus in China and its rapid spread is rattling countries, only the collective international experience and advances derived from past outbreaks can accelerate its control.

Single-cell genomic approaches for developing the next generation of immunotherapies

Nature Medicine
Volume 26 Issue 2, February 2020
https://www.nature.com/nm/volumes/26/issues/2

 

Perspective | 03 February 2020
Single-cell genomic approaches for developing the next generation of immunotherapies
Amit and colleagues discuss where single-cell genomic technologies can be applied both in trial design and in the clinical trial stage to improve the development of immunotherapies.
Ido Yofe, Rony Dahan & Ido Amit

Chromosome-free bacterial cells are safe and programmable platforms for synthetic biology

PNAS – Proceedings of the National Academy of Sciences of the United States of America
http://www.pnas.org/content/early/
[Accessed 7 Mar 2020]

 

Chromosome-free bacterial cells are safe and programmable platforms for synthetic biology
Catherine Fan, Paul A. Davison, Robert Habgood, Hong Zeng, Christoph M. Decker, Manuela Gesell Salazar, Khemmathin Lueangwattanapong, Helen E. Townley, Aidong Yang, Ian P. Thompson, Hua Ye, Zhanfeng Cui, Frank Schmidt, C. Neil Hunter, and Wei E. Huang
PNAS first published March 6, 2020. https://doi.org/10.1073/pnas.1918859117

Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 7 Mar 2020]

 

Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports
To assess the benefits and harms of the human papillomavirus (HPV) vaccines.
Authors: Lars Jørgensen, Peter C. Gøtzsche and Tom Jefferson
Citation: Systematic Reviews 2020 9:43
Content type: Research
Published on: 28 February 2020

Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 7 Mar 2020]

 

Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports
To assess the benefits and harms of the human papillomavirus (HPV) vaccines.
Authors: Lars Jørgensen, Peter C. Gøtzsche and Tom Jefferson
Citation: Systematic Reviews 2020 9:43
Content type: Research
Published on: 28 February 2020

What the systematic review of HPV vaccine clinical study reports does, and does not, reveal: commentary on Jørgensen et al.

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 7 Mar 2020]

 

What the systematic review of HPV vaccine clinical study reports does, and does not, reveal: commentary on Jørgensen et al.
Authors: Hilda Bastian
Citation: Systematic Reviews 2020 9:41
Content type: Commentary
Published on: 28 February 2020

What the systematic review of HPV vaccine clinical study reports does, and does not, reveal: commentary on Jørgensen et al.

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 7 Mar 2020]

 

What the systematic review of HPV vaccine clinical study reports does, and does not, reveal: commentary on Jørgensen et al.
Authors: Hilda Bastian
Citation: Systematic Reviews 2020 9:41
Content type: Commentary
Published on: 28 February 2020

Another coronavirus, another epidemic, another warning

Vaccine
Volume 38, Issue 10 Pages 2273-2432 (28 February 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/10

 

Editorial Full text access
Another coronavirus, another epidemic, another warning
Gregory A. Poland
[Excerpt]
Many questions must yet be answered as coronavirus vaccines are developed. Research questions whose answers have immediate and practical application include these issues:
:: Further resolution of case-fatality rates, viral reproductive number, and serosurveys that allow us to better appreciate the epidemiology of this infection
:: The identification and role of possible super-spreaders
:: Propensities for differential infection and transmission rates, as well as disease severity and fatality by age and ethnicity
:: Development of suitable animal models that closely mimic human pathophysiology and immunology must be identified and better optimized
:: Regulatory pathways for vaccine clinical trials and licensure in the absence of continuing outbreaks must be determined, as history demonstrates the intermittent and sudden appearance of outbreaks with these novel viruses—how might such regulatory pathways be altered in the event of a pandemic or more lethal mutations?
:: How shall issues of immunosensecence in the elderly and immunoimmaturity in infants and children be accounted for?
:: Why have we not seen widespread or lethal infections in children compared to adults?
:: What about special populations such as health care providers, pregnant women, immunocompromised individuals, and those with and without prior experience with various types of coronavirus infection?
:: How will such vaccines be equitably distributed—particularly in low income countries?
:: Better data on viral pathogenesis and human immune responses

As the world waits and watches, it is apparent that Chinese authorities in particular, and all countries, must take more seriously the threat of these emerging coronavirus human pathogens. Specific steps should include the following:
:: Regulate so-called wet markets with bans on the unregulated sale and trade in exotic animals.
:: Improve sanitation in such markets with food protection and hygienic standards appropriate to 21st century practices.
:: Significantly expand public health infrastructure. Among such tasks must be the regular surveillance of these markets for emerging viruses of concern.
:: Transparently, quickly, and in accordance with international health regulations, share information with global health authorities. The current outbreak is highly likely to have started in November or earlier, but it was not until late December that Chinese authorities reported to the WHO what was happening.
:: Allow, from the very beginning, health authorities from across the globe to assist in outbreak investigation and scientific investigation. It is surprising that CDC has not yet been invited to China to assist in this global issue. It is surprising to see papers from Chinese scientists that place barriers on sharing information—such as requiring “detailed study protocols and statistical and reporting plans” submitted for approval before data is shared. This is counter to the essence of professionalism and moral imperatives to openly share science for the protection of the health of the global public.